AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $12.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$12.2M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 1 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 10+ awardsAwards on record
Key stats
Fundamentals Oct 1- Open
- $89.24
- 52-wk high
- $91.99
- High
- $91.99
- 52-wk low
- $11.16
- Low
- $87.29
- Prev close
- $88.50
- Mkt cap
- $11.73B
- Volume
- 3.45M
- Fwd P/E
- 1250.0x
- Beta
- 2.08
- P/S
- 19.0x
- P/B
- 11.9x
- Profit margin
- -12.2%
- Op margin
- -15.2%
- ROE
- -9.4%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about TXG filings
Are insiders buying or selling 10X Genomics Inc (TXG) stock?
Net selling: insiders sold $12.2M and bought $0 of TXG stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $6.7M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Taich, Adam (Chief Financial Officer), who sold $4.1M. The latest filing was on Sep 24, 2026.
Which members of Congress have traded TXG recently?
None. No member of Congress disclosed a TXG trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this TXG smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- CI
Citadel
$90.8M
added
- P7
Point72
$71.0M
bought
Sells/Trims (1)
- MI
Millennium
$39.4M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in TXG right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 39.1% above what analysts expected.
Earnings per share
-$0.23 expected
Reports Nov 5, 2026, in 35 days
Estimates as of Sep 29, 2026
EPS expected
-$0.04 to $0.00
Revenue expected
16 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $149.0M | $166.0M | $150.8M | $151.0M |
| Cost of what it sold | $48.7M | $53.0M | $44.7M | $38.5M |
| Gross profit | $100.3M | $113.0M | $106.2M | $112.5M |
| What it spent | ||||
| Research and development | $57.2M | $56.0M | $56.8M | $56.8M |
| Sales and admin | $75.4M | $76.6M | $66.4M | $78.7M |
| Other operating costs | — | — | — | -$3.4M |
| Total operating expenses | $132.5M | $132.6M | $123.2M | $132.1M |
| What was left | ||||
| Operating profit | -$32.2M | -$19.5M | -$17.0M | -$19.6M |
| Interest on debt | $3.0K | — | — | $0 |
| Profit before tax | -$28.2M | -$15.2M | -$12.8M | -$18.6M |
| Tax | -$733.0K | $1.1M | $623.0K | -$714.0K |
| Net profit | -$27.5M | -$16.3M | -$13.5M | -$17.9M |
| EBITDA | -$16.0M | $63.5M | -$937.0K | -$18.6M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace